SLN250117P10000
- 0.00
- 0.000.00%
Silence Therapeutics Newsroom
Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $55
Silence Therapeutics Is Maintained at Buy by Chardan Capital
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Silence Therapeutics (SLN)
Silence Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $67
Silence Therapeutics: Anticipated Zerlasiran Partnership and Favorable Pelacarsen CVOT Outlook Drive Buy Rating
Silence Therapeutics Analyst Ratings
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $55
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Silence Therapeutics Analyst Ratings
Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $55
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Buy Rating for Silence Therapeutics: Promising Phase 1 Results and Future Prospects